All stock lists
Greenwich LifeSciences, Inc. (NASDAQ:GLSI)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$14.94-$0.34 (-2.23%)
Market cap
$219M
Insider Score
Health Score
Analyst consensus
Listed since
Sep 25, 2020
Website
Insider Score
––Not scored
GLSI Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From GLSI’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$21.7M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $8.9M
- Debt / equity
- 0.00
Liquidity14 / 20
Comfortably covers what is due within a year.
- Current assets
- $8.9M
- Current liabilities
- $5.8M
- Current ratio
- 1.54
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$12.5M
- Free cash flow
- -$12.5M
Dilution & runway3 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 14.6M
- Share growth (1y)
- 9.4%
- Cash runway
- 9 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
GLSI Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $876.00 | $903.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | -$876.00 | -$903.00 |
| SG&A Expense | $462.93 K | $518.19 K | $653.07 K | $653.07 K | $538.05 K | $496.70 K |
| R&D Expense | $3.56 M | $5.21 M | $3.52 M | $3.52 M | $3.51 M | $2.27 M |
| Operating Expenses | $4.02 M | $5.73 M | $7.94 M | $4.17 M | $4.05 M | $2.77 M |
| Operating Income | -$4.02 M | -$5.73 M | -$7.94 M | -$4.17 M | -$4.05 M | -$2.77 M |
| Pretax Income | -$3.95 M | -$5.66 M | -$7.92 M | -$4.15 M | -$4.03 M | -$2.74 M |
| Tax Provision | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$3.95 M | -$5.66 M | -$7.92 M | -$4.15 M | -$4.03 M | -$2.74 M |
| EPS (Basic) | -$0.27 | -$0.39 | -$0.58 | -$0.30 | -$0.30 | -$0.25 |
| EPS (Diluted) | -$0.27 | -$0.39 | -$0.58 | -$0.30 | -$0.30 | -$0.25 |
| Shares Outstanding | 14.62 M | 14.57 M | 13.64 M | 13.64 M | 13.37 M | 13.17 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.